Jean Park

Cooley advised DigitalOcean Holdings (NYSE: DOCN), a simple, scalable cloud platform that democratizes cloud and artificial intelligence for digital native enterprises around the world, on its $625 million aggregate principal amount of convertible senior notes due 2030 in a private offering pursuant to Rule 144A under the Securities Act of 1933, including the exercise in full of the initial purchasers’ option to purchase up to an additional $75 million aggregate principal amount of the notes.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised DEFCON AI, an insights company that’s building a next-generation modeling, simulation and analysis tool set for the modern military environment, on its $44 million in Seed financing.